Acura Pharmaceuticals, INC

Acura Pharmaceuticals, Inc. announced a new $200,000 loan from Abuse Deterrent Pharma, LLC, bringing the total outstanding principal to $10,894,279, as the company faces potential operational scaling back or bankruptcy if further financing is not secured by mid-August 2026.

Acura Pharmaceuticals has amended its loan agreement with AD Pharma, extending the principal and interest due date to December 31, 2026, and has also extended the FDA New Drug Application acceptance date for LTX-03 to the same date.

Acura Pharmaceuticals reports new loan agreements totaling $100,000 on multiple dates in March and April 2026, bringing the total principal balance of its secured promissory note to $10,294,279.

Acura Pharmaceuticals has secured additional loans from Abuse Deterrent Pharma, LLC, but warns of potential bankruptcy without further financing by end of January 2026.

Acura Pharmaceuticals has extended critical FDA submission and debt maturity deadlines to June 30, 2026, while securing additional financing from its majority shareholder, Abuse Deterrent Pharma, LLC.

Acura Pharmaceuticals received additional loans from Abuse Deterrent Pharma, LLC, increasing its total debt to $8.99 million, while explicitly warning of potential bankruptcy and complete loss of shareholder value without further financing by early November 2025.

ACURA Pharmaceuticals Director Immanuel Thangaraj reported the exchange of restricted stock units for common stock and a new RSU grant, aligning executive interests.

Acura Pharmaceuticals Director William G. Skelly converted 50,000 restricted stock units into common stock and received a new grant of 50,000 restricted stock units.

Acura Pharmaceuticals Director George K. Ross reported an exchange of restricted stock units for common stock and received a new RSU grant.

Director Immanuel Thangaraj exercises restricted stock units for Acura Pharmaceuticals common stock and receives additional units.

Director William Skelly of Acura Pharmaceuticals acquired 50,000 shares of common stock through the exchange of restricted stock units on January 2, 2025.

Director George K. Ross exercised 50,000 restricted stock units for common stock and received a new grant of 50,000 restricted stock units.